title: 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites.
abstract: Treatment induces reactive changes that often resemble low-grade dysplasia at former oral cancer sites, complicating histopathological assessment. We tested a set of microsatellite markers shown previously to be predictive of progression for oral premalignant lesions for the ability to predict development of second oral malignancy (SOM). Sixty-eight oral leukoplakia at former cancer sites (with known outcome, 36 progressed to SOM) were evaluated for loss of heterozygosity at 19 loci on seven chromosome arms. 3p and/or 9p loss in these posttreatment leukoplakia was associated with a 26.3-fold increase in risk of developing SOM compared with those that retained both of these arms (P < 0.001), with 60% of cases with loss of heterozygosity developing SOM in 2 years. In contrast, histological diagnosis (moderate or severe dysplasia versus hyperplasia or mild dysplasia) had only a 1.7-fold increase in risk (P = 0.11). The identification of 3p and 9p loss in posttreatment lesions could serve as a simple and direct test for stratifying risk of SOM development.
authors.affiliation: British Columbia Cancer Research Centre, Vancouver, British Columbia, V5Z 1L3, Canada.
authors.forename: Miriam P
authors.initials: MP
authors.lastname: Rosin
authors.forename: Wan L
authors.initials: WL
authors.lastname: Lam
authors.forename: Catherine
authors.initials: C
authors.lastname: Poh
authors.forename: Nhu D
authors.initials: ND
authors.lastname: Le
authors.forename: Robert Jinze
authors.initials: RJ
authors.lastname: Li
authors.forename: Tao
authors.initials: T
authors.lastname: Zeng
authors.forename: Robert
authors.initials: R
authors.lastname: Priddy
authors.forename: Lewei
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002278:Carcinoma in Situ / Q000235:genetics / Q000473:pathology / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology / Q000628:therapy; D002893:Chromosomes, Human, Pair 3 / Q000235:genetics*; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D007972:Leukoplakia, Oral / Q000235:genetics / Q000473:pathology; D019656:Loss of Heterozygosity; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000235:genetics* / Q000473:pathology; D011237:Predictive Value of Tests